Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;44(4):682-687.
doi: 10.1002/npr2.12469. Epub 2024 Nov 4.

Effects of frequently prescribed antiseizure medications on motor vehicle driving performance: Narrative review based on a tiered approach for the assessment of clinically meaningful driving impairment in the Ministry of Health, Labour, and Welfare guideline

Affiliations
Review

Effects of frequently prescribed antiseizure medications on motor vehicle driving performance: Narrative review based on a tiered approach for the assessment of clinically meaningful driving impairment in the Ministry of Health, Labour, and Welfare guideline

Kunihiro Iwamoto et al. Neuropsychopharmacol Rep. 2024 Dec.

Abstract

Patients with epilepsy often require long-term treatment with antiseizure medications, and their impact on daily activities, particularly driving, is of significant concern. The recently published "Guideline for Evaluating Effects of Psychotropic Drugs on the Performance to Drive a Motor Vehicle" in Japan provides a framework that can be referred to for not only the evaluation of new drugs but also the reevaluation of approved drugs. This study conducted a literature review regarding the effects of carbamazepine, valproate, lamotrigine, lacosamide, and levetiracetam, which are frequently prescribed for epilepsy, on driving performance following the guideline's tiered evaluation approach. Analyses of pharmacological, pharmacodynamic, and adverse events suggested that these drugs primarily affect arousal function. Driving studies showed that acute administration of carbamazepine, but not chronic monotherapy with carbamazepine, valproate, lamotrigine, and levetiracetam, significantly impairs driving performance. Epidemiological studies have not identified a definitive association between these drugs and traffic accidents. Initial administration of these five antiseizure medications may affect driving performance, warranting special attention, but the influence appears to diminish with continued use. Nevertheless, while long-term administration of these five drugs may not have a clinically meaningful effect on driving performance, safe driving is not guaranteed for each individual patient, and appropriate individualized guidance is important in clinical practice.

Keywords: antiseizure medication; driving performance; drug evaluation; guideline; traffic accident.

PubMed Disclaimer

Conflict of interest statement

KI has received speakers' honoraria from Eisai, Kyowa, Meiji Seika Pharma, MSD, Otsuka, Sumitomo Pharma, Takeda, Towa, and Viatris, outside the submitted work. RY has received speakers' honoraria from Sumitomo Pharma, Eisai, Otsuka, and Viatris, outside the submitted work. KK has received speaker's honoraria from Eisai, Daiichi‐Sankyo, Otsuka, and UCB pharmaceutical companies, outside the submitted work. MA has received subsidies from Kyowa Kirin. NO has received research support or speakers' honoraria from, or has served as a joint researcher with, or a consultant to, Sumitomo Pharma, Otsuka, Viatris, Eisai, Mochida, Kyowa Pharmaceutical Industry, Nihon Medi‐Physics, Nippon Chemiphar, Medical Review, Nippon Boehringer Ingelheim, and SUSMED, outside the submitted work. The other authors have no conflicts of interest to declare. Board member is coauthor: R. Yoshimura is an editorial board member of Neuropsychopharmacology Reports and a coauthor of this article. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication.

The views expressed in this article are those of the authors and do not necessarily reflect the official views of the Pharmaceuticals and Medical Devices Agency.

Figures

FIGURE 1
FIGURE 1
Flowchart of the tiered approach for evaluating the effects of antiseizure medications on motor vehicle driving performance. BAC, blood alcohol concentration; MHLW, Ministry of Health, Labour, and Welfare; SDLP, standard deviation of lateral position.

Similar articles

References

    1. Ravera S, Monteiro SP, de Gier JJ, van der Linden T, Gómez‐Talegón T, Álvarez FJ, et al. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 2012;74(6):920–931. - PMC - PubMed
    1. Willems LM, van der Goten M, von Podewils F, Knake S, Kovac S, Zöllner JP, et al. Adverse event profiles of antiseizure medications and the impact of coadministration on drug tolerability in adults with epilepsy. CNS Drugs. 2023;37(6):531–544. - PMC - PubMed
    1. Iwamoto K, Nakabayashi T, Yamaguchi A, Konishi Y, Saji M, Yoshimura R, et al. The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: comparison with US FDA guideline. Neuropsychopharmacol Rep. 2023;43(2):172–176. - PMC - PubMed
    1. Nakabayashi T, Iwamoto K, Yamaguchi A, Konishi Y, Saji M, Yoshimura R, et al. Guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance in Japan: a tiered approach for the assessment of clinically meaningful driving impairment. Neuropsychopharmacol Rep. 2024;44:308–313. - PMC - PubMed
    1. Löscher W, Klein P. The pharmacology and clinical efficacy of Antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935–963. - PMC - PubMed

MeSH terms

Substances